论文部分内容阅读
二肽基肽酶4（DPP－4）抑制剂通过延缓胰升糖素样多肽1（GLP－1）、糖依赖性胰岛素释放肽（ GIP）降解而延长生理性GLP－1作用时间达到降低血糖的作用，除此之以外它的众多胰腺外作用逐渐被发现。 DPP－4抑制剂可以安全的单独使用及和与多种口服降糖药物、及胰岛素联合使用，不影响体质量，不增加低血糖发生风险，性价比较高，在临床上逐渐广泛应用广泛，有良好的应用前景，已成为治疗2型糖尿病的又一个有力武器。“,”Dipeptidylpeptidase 4(DPP-4) inhibitors by slowing down glucagon-like peptide-1(GLP-1), glucose dependent insulinotropic peptide degradation and prolonging the acting time of physiologic GLP-1 to lower blood sugar action,besides its multiple functions besides pancreas function were gradually found .DPP-4 inhibitors can be safely used alone and in combination with a variety of oral hypoglycemic drugs and insu-lin,which does not affect the body weight,does not increase the risk of hypoglycaemia,and has high cost per-formance ratio,and is being widely used in clinical gradually,with good application prospect,which has become another powerful weapon for the treatment of type 2 diabetes mellitus.